Pharmaceutical

Request for TOC Request for Sample
BUY NOW

North America Down Syndrome Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Mar 2021 | North America | 350 Pages | No of Tables: 597 | No of Figures: 46

Report Description

North America Down Syndrome Market, By Disease Type (Trisomy 21, Translocation Down Syndrome and Mosaic Down Syndrome), Treatment (Diagnosis and Therapy), End User (Hospital, Clinics, Homecare Setting, Therapy Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: North America Down Syndrome Market

North America Down syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 14.1% in the forecast period of 2021 to 2028 and is expected to reach USD 1,973.96 million by 2028.

Presence of pipeline therapies and increasing prevalence of Down syndrome and other related disorders are the major drivers which propelled the demand of the market in the forecast period.

Down syndrome comprises features such as increasing need for safe and effective product will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative Down syndrome products which is expected to provide various other opportunities in the Down syndrome market. However, unavailability of registered Down syndrome and presence of reimbursement expected to restraint the market growth in the forecast period.

The Down syndrome market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

North America Down Syndrome Market Scope and Market Size

The Down syndrome market is categorized into four notable segments which are based on disease type, treatment, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the Down syndrome market is segmented into trisomy 21, translocation Down syndrome and mosaic down syndrome. In 2021, trisomy 21 is dominating the market as it is the most common type of condition as compared to other rare forms of Down syndrome.
  • On the basis of treatment, the Down syndrome market is segmented into diagnosis and therapy. In 2021, diagnosis segment is dominating the market as most expecting mothers undergo routine prenatal testing for different types of disorders.
  • On the basis of end user, the Down syndrome market is segmented into hospital, clinics, homecare setting, therapy centers and others. In 2021, hospital segment is dominating the market because of presence of highly skilled professionals at hospitals. Moreover hospital have audiologists, physiotherapist among others who are especially engaged in providing specific treatment for Down syndrome associated complications.
  • On the basis of distribution channel, the Down syndrome market is segmented into direct tender, retail sales and others. In 2021, direct tenders are dominating in the market as direct tender are the primary source of diagnostic tool procurement and most of the healthcare facilities procures these directly from direct tenders at lower cost.

Down Syndrome Market Country Level Analysis

The Down syndrome market is analyzed and market size information is provided on the basis of disease type, treatment, end user and distribution channel.

The countries covered in the Down syndrome market report are the U.S., Canada and Mexico.

The North America region holds the majority of the share in the Down syndrome market and is expected to witness high CAGR during the forecast period due to high diagnosis and treatment rate. The U.S. has the highest medical spending in the world and large companies focus on management of Down syndrome making it the largest market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Awareness about the Disease and Strategic Initiatives by Market Players are boosting the Market Growth of Down Syndrome

Down syndrome market also provides you with detailed market analysis for every country growth in Down syndrome industry with Down syndrome drugs sales, impact of advancement in the Down syndrome technology and changes in regulatory scenarios with their support for the Down syndrome market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Down syndrome Market Share Analysis

Down syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Down syndrome market.

The major companies which are dealing in the Down syndrome are Natera, Inc., Next Biosciences, AtilaBiosystems, Myriad Genetics, Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Demeditec Diagnostics GmbH, Thermo Fisher Scientific Inc., Abnova Corporation, Novus Biologicals (a subsidiary of Bio-Techne, Mayo Clinic Health System, Boys Town National Research Hospital, Boston Children's Hospital, Children's Hospital Colorado, ASDclinic.co.uk, Symbol, Abbott, Physio.co.uk., Illumina, Inc. among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the Down syndrome market.

  • In November 2019, F. Hoffmann-La Roche Ltd received approval for Harmony test, first non-invasive prenatal test by Health Canada. The Harmony test is highly adopted for determining the probability of trisomy 21 and other common types of aneuploidies. This approval helped the company to penetrate across several region of the world and to boost up its revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the Down syndrome market which also provides the benefit for organization to improve their offering for Down syndrome.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA DOWN SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT OF DOWN SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 NORTH AMERICA DOWN SYNDROME MARKET: PIPELINE ANALYSIS

4.1 PIPELINE PRODUCTS IMPACT ANALYSIS

4.2 NNI-351

4.3 ASPARAGINASE

4.4 ANVS-401

4.5 QUILLIVANT XR

4.6 TOFACITINIB

4.7 MEMANTINE HYDROCHLORIDE

4.8 NICOTINE

4.9 AEF0217

4.1 ACI-24

5 NORTH AMERICA DOWN SYNDROME MARKET: LAWS AND REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF DOWN SYNDROME

6.1.2 RISING DEMAND OF EFFECTIVE THERAPIES

6.1.3 RISING AWARENESS ABOUT THE DISEASE

6.1.4 TECHNOLOGICAL ADVANCEMENTS

6.1.5 INCREASING GOVERNMENT SUPPORT

6.2 RESTRAINTS

6.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

6.2.2 SIDE EFFECTS ASSOCIATED WITH DOWN SYNDROME TREATMENT THERAPIES

6.2.3 HIGH COST OF DIAGNOSIS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT

6.3.3 PRESENCE OF PIPELINE THERAPIES

6.3.4 PRESENCE OF REIMBURSEMENT

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFFESSIONALS

6.4.2 LONG PROCESS FOR PRODUCT LAUNCH

6.4.3 TRANSFER OF COVID-19 INFECTIONS BY DIAGNOSTIC METHODS

7 IMPACT OF COVID-19 ON NORTH AMERICA DOWN SYNDROME MARKET

7.1 PRICE IMPACT

7.2 IMPACT ON SUPPLY CHAIN

7.3 IMPACT ON DEMAND

7.4 STRATEGIC DECISIONS FOR MANUFACTURERS

7.5 CONCLUSION

8 NORTH AMERICA DOWN SYNDROME MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 TRISOMY 21

8.3 TRANSLOCATION DOWN SYNDROME

8.4 MOSAIC DOWN SYNDROME

9 NORTH AMERICA DOWN SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 SCREENING TESTS

9.2.1.1 First Trimester

9.2.1.1.1 Blood Test

9.2.1.1.2 Nuchal Translucency Testing

9.2.1.2 Integrated Screening Test

9.2.1.2.1 First Trimester

9.2.1.2.2 Second Trimester

9.2.1.3 The Triple Screen or Quadraple Screen Test

9.2.1.4 Ultrasound

9.2.1.5 Cell Free DNA

9.2.2 DIAGNOSTIC TESTS

9.2.2.1 Chronic Villus Sampling

9.2.2.2 Amniocentesis

9.2.2.3 Precutaneous Umbical Cord Sampling

9.3 THERAPY

9.3.1 EARLY INTERVENTION THERAPY

9.3.1.1 Speech-Language Therapy

9.3.1.2 Physical Therapy

9.3.1.3 Occupational Therapy

9.3.1.4 Others

9.3.2 ASSISTIVE TECHNOLOGY

9.3.2.1 Hearing Aids

9.3.2.2 Glasses

9.3.2.3 Others

9.3.3 SURGERY

9.3.3.1 Atrioventricular Septal Defect (AVSD)

9.3.3.2 Duodenal Atresia

9.3.3.3 Others

9.3.4 OTHERS

10 NORTH AMERICA DOWN SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL

10.3 CLINICS

10.4 HOMECARE SETTING

10.5 OTHERS

11 NORTH AMERICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 OTHERS

12 NORTH AMERICA DOWN SYNDROME MARKET, BY GEOGRAPHY

12.1 OVERVIEW

12.2 NORTH AMERICA

12.2.1 U.S.

12.2.2 CANADA

12.2.3 MEXICO

12.3 EUROPE

12.3.1 GERMANY

12.3.2 U.K.

12.3.3 FRANCE

12.3.4 ITALY

12.3.5 SPAIN

12.3.6 RUSSIA

12.3.7 POLAND

12.3.8 SWITZERLAND

12.3.9 NETHERLANDS

12.3.10 HUNGARY

12.3.11 AUSTRIA

12.3.12 NORWAY

12.3.13 IRELAND

12.3.14 TURKEY

12.3.15 LITHUANIA

12.3.16 REST OF EUROPE

12.4 ASIA-PACIFIC

12.4.1 CHINA

12.4.2 JAPAN

12.4.3 AUSTRALIA

12.4.4 SOUTH KOREA

12.4.5 INDIA

12.4.6 SINGAPORE

12.4.7 THAILAND

12.4.8 MALAYSIA

12.4.9 INDONESIA

12.4.10 PHILIPPINES

12.4.11 VIETNAM

12.4.12 REST OF ASIA-PACIFIC

12.5 SOUTH AMERICA

12.5.1 BRAZIL

12.5.2 ARGENTINA

12.5.3 PERU

12.5.4 REST OF SOUTH AMERICA

12.6 MIDDLE EAST & AFRICA

12.6.1 SOUTH AFRICA

12.6.2 SAUDI ARABIA

12.6.3 UAE

12.6.4 ISRAEL

12.6.5 KUWAIT

12.6.6 EGYPT

12.6.7 REST OF MIDDLE EAST & AFRICA

13 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

13.3 COMPANY SHARE ANALYSIS: EUROPE

13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 COMPANY PROFILE

14.1 F. HOFFMANN-LA ROCHE LTD

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 PERKINELMER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 ILLUMINA, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 MYRIAD GENETICS, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ABBOTT

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ABNOVA CORPORATION

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENTS

14.8 ASDCLINIC.CO.UK

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ATILABIOSYSTEMS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BOSTON CHILDREN'S HOSPITAL

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BOYS TOWN NATIONAL RESEARCH HOSPITAL

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 CHILDREN'S HOSPITAL COLORADO

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 DEMEDITEC DIAGNOSTICS GMBH

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 DOWN SYNDROME CORK

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 MAYO CLINIC HEALTH SYSTEM

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 NATERA, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 NEXT BIOSCIENCES

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 NOVUS BIOLOGICALS (A SUBSIDIARY OF BIO-TECHNE)

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 KID SENSE CHILD DEVELOPMENT CORPORATION PTY LTD

14.19.1 COMPANY SNAPSHOT

14.19.2 SERVICE PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 PHYSIO.CO.UK.

14.20.1 COMPANY SNAPSHOT

14.20.2 SERVICE PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SYMBOL

14.21.1 COMPANY SNAPSHOT

14.21.2 SERVICE PORTFOLIO

14.21.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 NORTH AMERICA DOWN SYNDROME MARKET: PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 NORTH AMERICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA TRISOMY 21 IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA TRANSLOCATION DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA MOSAIC DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA INTEGRATED SCREENING TEST IN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA THERAPY IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA THERAPY IN DOWN SYNDROM MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA HOSPITAL IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA CLINICS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA HOMECARE SETTING IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA THERAPY CENTERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA DIRECT TENDER IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA RETAIL SALES IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 44 U.S. DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 45 U.S. DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 46 U.S. DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 47 U.S. SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 48 U.S. FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 49 U.S. INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 50 U.S. DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 51 U.S. THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 52 U.S. EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 53 U.S. ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 54 U.S. SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 55 U.S. DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 56 U.S. DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 57 CANADA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 58 CANADA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 59 CANADA NORTH AMERICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 60 CANADA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 61 CANADA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 62 CANADA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 63 CANADA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 64 CANADA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 65 CANADA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 66 CANADA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 67 CANADA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 68 CANADA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 69 CANADA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 70 MEXICO DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 71 MEXICO DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 72 MEXICO DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 73 MEXICO SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 74 MEXICO FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 75 MEXICO INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 76 MEXICO DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 77 MEXICO THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 78 MEXICO EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 79 MEXICO ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 80 MEXICO SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 81 MEXICO DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 82 MEXICO DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 83 EUROPE DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 84 EUROPE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 85 EUROPE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 86 EUROPE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 87 EUROPE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 88 EUROPE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 89 EUROPE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 90 EUROPE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 91 EUROPE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 92 EUROPE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 93 EUROPE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 94 EUROPE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 95 EUROPE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 96 EUROPE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 97 GERMANY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 98 GERMANY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 99 GERMANY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 100 GERMANY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 101 GERMANY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 102 GERMANY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 103 GERMANY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 104 GERMANY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 105 GERMANY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 106 GERMANY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 107 GERMANY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 108 GERMANY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 109 GERMANY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 110 U.K. DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 111 U.K. DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 112 U.K. DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 113 U.K. SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 114 U.K. FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 115 U.K. INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 116 U.K. DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 117 U.K. THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 118 U.K. EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 119 U.K. ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 120 U.K. SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 121 U.K. DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 122 U.K. DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 123 FRANCE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 124 FRANCE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 125 FRANCE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 126 FRANCE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 127 FRANCE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 128 FRANCE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 129 FRANCE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 130 FRANCE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 131 FRANCE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 132 FRANCE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 133 FRANCE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 134 FRANCE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 135 FRANCE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 136 ITALY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 137 ITALY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 138 ITALY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 139 ITALY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 140 ITALY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 141 ITALY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 142 ITALY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 143 ITALY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 144 ITALY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 145 ITALY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 146 ITALY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 147 ITALY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 148 ITALY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 149 SPAIN DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 150 SPAIN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 151 SPAIN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 152 SPAIN SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 153 SPAIN FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 154 SPAIN INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 155 SPAIN DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 156 SPAIN THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 157 SPAIN EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 158 SPAIN ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 159 SPAIN SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 160 SPAIN DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 161 SPAIN DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 162 RUSSIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 163 RUSSIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 164 RUSSIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 165 RUSSIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 166 RUSSIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 167 RUSSIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 168 RUSSIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 169 RUSSIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 170 RUSSIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 171 RUSSIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 172 RUSSIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 173 RUSSIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 174 RUSSIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 175 POLAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 176 POLAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 177 POLAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 178 POLAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 179 POLAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 180 POLAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 181 POLAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 182 POLAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 183 POLAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 184 POLAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 185 POLAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 186 POLAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 187 POLAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 188 SWITZERLAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 189 SWITZERLAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 190 SWITZERLAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 191 SWITZERLAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 192 SWITZERLAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 193 SWITZERLAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 194 SWITZERLAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 195 SWITZERLAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 196 SWITZERLAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 197 SWITZERLAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 198 SWITZERLAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 199 SWITZERLAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 200 SWITZERLAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 201 NETHERLANDS DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 202 NETHERLANDS DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 203 NETHERLANDS DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 204 NETHERLANDS SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 205 NETHERLANDS FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 206 NETHERLANDS INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 207 NETHERLANDS DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 208 NETHERLANDS THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 209 NETHERLANDS EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 210 NETHERLANDS ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 211 NETHERLANDS SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 212 NETHERLANDS DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 213 NETHERLANDS DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 214 HUNGARY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 215 HUNGARY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 216 HUNGARY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 217 HUNGARY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 218 HUNGARY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 219 HUNGARY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 220 HUNGARY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 221 HUNGARY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 222 HUNGARY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 223 HUNGARY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 224 HUNGARY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 225 HUNGARY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 226 HUNGARY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 227 AUSTRIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 228 AUSTRIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 229 AUSTRIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 230 AUSTRIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 231 AUSTRIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 232 AUSTRIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 233 AUSTRIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 234 AUSTRIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 235 AUSTRIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 236 AUSTRIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 237 AUSTRIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 238 AUSTRIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 239 AUSTRIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 240 NORWAY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 241 NORWAY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 242 NORWAY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 243 NORWAY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 244 NORWAY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 245 NORWAY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 246 NORWAY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 247 NORWAY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 248 NORWAY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 249 NORWAY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 250 NORWAY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 251 NORWAY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 252 NORWAY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 253 IRELAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 254 IRELAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 255 IRELAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 256 IRELAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 257 IRELAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 258 IRELAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 259 IRELAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 260 IRELAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 261 IRELAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 262 IRELAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 263 IRELAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 264 IRELAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 265 IRELAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 266 TURKEY DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 267 TURKEY DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 268 TURKEY DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 269 TURKEY SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 270 TURKEY FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 271 TURKEY INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 272 TURKEY DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 273 TURKEY THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 274 TURKEY EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 275 TURKEY ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 276 TURKEY SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 277 TURKEY DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 278 TURKEY DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 279 LITHUANIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 280 LITHUANIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 281 LITHUANIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 282 LITHUANIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 283 LITHUANIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 284 LITHUANIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 285 LITHUANIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 286 LITHUANIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 287 LITHUANIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 288 LITHUANIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 289 LITHUANIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 290 LITHUANIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 291 LITHUANIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 292 REST OF EUROPE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 293 ASIA-PACIFIC DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 294 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 295 ASIA-PACIFIC DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 296 ASIA-PACIFIC DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 297 ASIA-PACIFIC SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 298 ASIA-PACIFIC FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 299 ASIA-PACIFIC INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 300 ASIA-PACIFIC DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 301 ASIA-PACIFIC THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 302 ASIA-PACIFIC EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 303 ASIA-PACIFIC ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 304 ASIA-PACIFIC SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 305 ASIA-PACIFIC DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 306 ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 307 CHINA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 308 CHINA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 309 CHINA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 310 CHINA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 311 CHINA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 312 CHINA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 313 CHINA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 314 CHINA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 315 CHINA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 316 CHINA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 317 CHINA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 318 CHINA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 319 CHINA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 320 JAPAN DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 321 JAPAN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 322 JAPAN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 323 JAPAN SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 324 JAPAN FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 325 JAPAN INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 326 JAPAN DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 327 JAPAN THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 328 JAPAN EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 329 JAPAN ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 330 JAPAN SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 331 JAPAN DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 332 JAPAN DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 333 AUSTRALIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 334 AUSTRALIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 335 AUSTRALIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 336 AUSTRALIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 337 AUSTRALIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 338 AUSTRALIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 339 AUSTRALIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 340 AUSTRALIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 341 AUSTRALIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 342 AUSTRALIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 343 AUSTRALIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 344 AUSTRALIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 345 AUSTRALIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 346 SOUTH KOREA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 347 SOUTH KOREA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 348 SOUTH KOREA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 349 SOUTH KOREA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 350 SOUTH KOREA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 351 SOUTH KOREA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 352 SOUTH KOREA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 353 SOUTH KOREA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 354 SOUTH KOREA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 355 SOUTH KOREA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 356 SOUTH KOREA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 357 SOUTH KOREA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 358 SOUTH KOREA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 359 INDIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 360 INDIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 361 INDIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 362 INDIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 363 INDIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 364 INDIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 365 INDIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 366 INDIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 367 INDIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 368 INDIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 369 INDIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 370 INDIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 371 INDIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 372 SINGAPORE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 373 SINGAPORE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 374 SINGAPORE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 375 SINGAPORE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 376 SINGAPORE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 377 SINGAPORE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 378 SINGAPORE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 379 SINGAPORE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 380 SINGAPORE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 381 SINGAPORE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 382 SINGAPORE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 383 SINGAPORE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 384 SINGAPORE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 385 THAILAND DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 386 THAILAND DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 387 THAILAND DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 388 THAILAND SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 389 THAILAND FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 390 THAILAND INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 391 THAILAND DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 392 THAILAND THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 393 THAILAND EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 394 THAILAND ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 395 THAILAND SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 396 THAILAND DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 397 THAILAND DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 398 MALAYSIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 399 MALAYSIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 400 MALAYSIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 401 MALAYSIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 402 MALAYSIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 403 MALAYSIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 404 MALAYSIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 405 MALAYSIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 406 MALAYSIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 407 MALAYSIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 408 MALAYSIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 409 MALAYSIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 410 MALAYSIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 411 INDONESIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 412 INDONESIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 413 INDONESIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 414 INDONESIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 415 INDONESIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 416 INDONESIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 417 INDONESIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 418 INDONESIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 419 INDONESIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 420 INDONESIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 421 INDONESIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 422 INDONESIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 423 INDONESIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 424 PHILIPPINES DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 425 PHILIPPINES DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 426 PHILIPPINES DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 427 PHILIPPINES SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 428 PHILIPPINES FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 429 PHILIPPINES INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 430 PHILIPPINES DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 431 PHILIPPINES THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 432 PHILIPPINES EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 433 PHILIPPINES ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 434 PHILIPPINES SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 435 PHILIPPINES DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 436 PHILIPPINES DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 437 VIETNAM DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 438 VIETNAM DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 439 VIETNAM DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 440 VIETNAM SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 441 VIETNAM FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 442 VIETNAM INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 443 VIETNAM DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 444 VIETNAM THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 445 VIETNAM EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 446 VIETNAM ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 447 VIETNAM SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 448 VIETNAM DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 449 VIETNAM DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 450 REST OF ASIA-PACIFIC DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 451 SOUTH AMERICA DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 452 SOUTH AMERICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 453 SOUTH AMERICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 454 SOUTH AMERICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 455 SOUTH AMERICA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 456 SOUTH AMERICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 457 SOUTH AMERICA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 458 SOUTH AMERICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 459 SOUTH AMERICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 460 SOUTH AMERICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 461 SOUTH AMERICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 462 SOUTH AMERICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 463 SOUTH AMERICA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 464 SOUTH AMERICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 465 BRAZIL DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 466 BRAZIL DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 467 BRAZIL DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 468 BRAZIL SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 469 BRAZIL FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 470 BRAZIL INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 471 BRAZIL DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 472 BRAZIL THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 473 BRAZIL EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 474 BRAZIL ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 475 BRAZIL SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 476 BRAZIL DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 477 BRAZIL DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 478 ARGENTINA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 479 ARGENTINA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 480 ARGENTINA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 481 ARGENTINA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 482 ARGENTINA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 483 ARGENTINA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 484 ARGENTINA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 485 ARGENTINA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 486 ARGENTINA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 487 ARGENTINA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 488 ARGENTINA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 489 ARGENTINA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 490 ARGENTINA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 491 PERU DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 492 PERU DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 493 PERU DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 494 PERU SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 495 PERU FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 496 PERU INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 497 PERU DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 498 PERU THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 499 PERU EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 500 PERU ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 501 PERU SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 502 PERU DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 503 PERU DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 504 REST OF SOUTH AMERICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 505 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 506 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 507 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 508 MIDDLE EAST & AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 509 MIDDLE EAST & AFRICA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 510 MIDDLE EAST & AFRICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 511 MIDDLE EAST & AFRICA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 512 MIDDLE EAST & AFRICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 513 MIDDLE EAST & AFRICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 514 MIDDLE EAST & AFRICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 515 MIDDLE EAST & AFRICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 516 MIDDLE EAST & AFRICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 517 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 518 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 519 SOUTH AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 520 SOUTH AFRICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 521 SOUTH AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 522 SOUTH AFRICA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 523 SOUTH AFRICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 524 SOUTH AFRICA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 525 SOUTH AFRICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 526 SOUTH AFRICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 527 SOUTH AFRICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 528 SOUTH AFRICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 529 SOUTH AFRICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 530 SOUTH AFRICA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 531 SOUTH AFRICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 532 SAUDI ARABIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 533 SAUDI ARABIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 534 SAUDI ARABIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 535 SAUDI ARABIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 536 SAUDI ARABIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 537 SAUDI ARABIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 538 SAUDI ARABIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 539 SAUDI ARABIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 540 SAUDI ARABIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 541 SAUDI ARABIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 542 SAUDI ARABIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 543 SAUDI ARABIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 544 SAUDI ARABIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 545 UAE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 546 UAE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 547 UAE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 548 UAE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 549 UAE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 550 UAE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 551 UAE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 552 UAE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 553 UAE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 554 UAE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 555 UAE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 556 UAE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 557 UAE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 558 ISRAEL DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 559 ISRAEL DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 560 ISRAEL DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 561 ISRAEL SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 562 ISRAEL FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 563 ISRAEL INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 564 ISRAEL DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 565 ISRAEL THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 566 ISRAEL EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 567 ISRAEL ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 568 ISRAEL SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 569 ISRAEL DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 570 ISRAEL DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 571 KUWAIT DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 572 KUWAIT DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 573 KUWAIT DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 574 KUWAIT SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 575 KUWAIT FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 576 KUWAIT INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 577 KUWAIT DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 578 KUWAIT THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 579 KUWAIT EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 580 KUWAIT ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 581 KUWAIT SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 582 KUWAIT DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 583 KUWAIT DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 584 EGYPT DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 585 EGYPT DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 586 EGYPT DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 587 EGYPT SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 588 EGYPT FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 589 EGYPT INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 590 EGYPT DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 591 EGYPT THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 592 EGYPT EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 593 EGYPT ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 594 EGYPT SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 595 EGYPT DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 596 EGYPT DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 597 REST OF MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES

FIGURE 1 NORTH AMERICA DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DOWN SYNDROME MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE NORTH AMERICA DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DOWN SYNDROME MARKET

FIGURE 15 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 NORTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 NORTH AMERICA DOWN SYNDROME MARKET: BY REGION (2020)

FIGURE 15 NORTH AMERICA DOWN SYNDROME MARKET: BY REGION (2021 & 2028)

FIGURE 16 NORTH AMERICA DOWN SYNDROME MARKET: BY REGION (2020 & 2028)

FIGURE 17 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 18 NORTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 19 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 20 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 21 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 22 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 23 EUROPE DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 24 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 25 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 26 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 27 EUROPE DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 28 ASIA-PACIFIC DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 29 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 30 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 31 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 - 2028)

FIGURE 32 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT (2021 & 2028)

FIGURE 33 SOUTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 34 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 35 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 36 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 37 SOUTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 38 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 39 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 40 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 42 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 43 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

FIGURE 44 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

FIGURE 45 EUROPE DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

FIGURE 46 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES

FIGURE 1 NORTH AMERICA DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DOWN SYNDROME MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE NORTH AMERICA DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DOWN SYNDROME MARKET

FIGURE 15 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 NORTH AMERICA DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 NORTH AMERICA DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 NORTH AMERICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 NORTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 NORTH AMERICA DOWN SYNDROME MARKET: BY REGION (2020)

FIGURE 15 NORTH AMERICA DOWN SYNDROME MARKET: BY REGION (2021 & 2028)

FIGURE 16 NORTH AMERICA DOWN SYNDROME MARKET: BY REGION (2020 & 2028)

FIGURE 17 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 18 NORTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 19 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 20 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 21 NORTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 22 NORTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 23 EUROPE DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 24 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 25 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 26 EUROPE DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 27 EUROPE DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 28 ASIA-PACIFIC DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 29 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 30 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 31 ASIA-PACIFIC DOWN SYNDROME MARKET: BY COUNTRY (2021 - 2028)

FIGURE 32 ASIA-PACIFIC DOWN SYNDROME MARKET: BY TREATMENT (2021 & 2028)

FIGURE 33 SOUTH AMERICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 34 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 35 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 36 SOUTH AMERICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 37 SOUTH AMERICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 38 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 39 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 40 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 42 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 43 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

FIGURE 44 NORTH AMERICA DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

FIGURE 45 EUROPE DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

FIGURE 46 ASIA-PACIFIC DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19